Status:
COMPLETED
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The McGill University Health Center (MUHC) Division of Cardiology, with funding from the Canadian Institute of Health Research, is performing this randomized controlled trial to determine which dual a...
Detailed Description
Acute Coronary Syndrome (ACS) is most often caused by erosion or rupture of an atherosclerotic plaque associated with inflammation, thrombus formation, vasoconstriction, and microembolisation. In unre...
Eligibility Criteria
Inclusion
- Patients that are prescribed a dual-antiplatelet therapy (DAPT) regimen following an acute coronary syndrome (ACS) event.
- ACS, with or without ST-segment elevation.
- STEMI and NSTEMI positive biomarkers and appropriate ECG changes will be required.
- NSTEMI patients with negative biomarkers are generally considered as unstable angina and will also be eligible for study inclusion if their treating physician has determined that DAPT is appropriate.
- Patients provided written informed consent.
Exclusion
- A decision from the patients attending physician to circumvent randomization and assign the patient a specific dual-antiplatelet therapy regimen.
- A contraindication to clopidogrel or ticagrelor
- Patients diagnosed with chronic total occlusion percutaneous coronary intervention (CTO PCI)
Key Trial Info
Start Date :
October 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2023
Estimated Enrollment :
1038 Patients enrolled
Trial Details
Trial ID
NCT04057300
Start Date
October 1 2018
End Date
April 1 2023
Last Update
November 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
McGill University Health Centre
Montreal, Quebec, Canada